Basmisanil Positron Emission Tomography Study in Japanese Volunteers
Completed
Hoffmann-La Roche
Phase 1
This study will evaluate the relationship between basmisanil plasma concentrations and the
occupancy of Gamma-Amino Butyric Acid A (GABAA) receptor subtypes containing an alpha5 (α5)
subunit in healthy Japanese volunteers. Each participant will have two post-screening imaging
sessions. In the first imaging session, participants will have a baseline Positron Emission
Tomography (PET) scan. In the second imaging session, participants will receive a single oral
dose of basmisanil, followed by two on-treatment PET scans at about 4 and 10 hours post-dose.
A Study to Evaluate the Safety and Efficacy of Basmisanil in Adults With Severe Motor Impairment Following an Ischemic Stroke
Terminated
Hoffmann-La Roche
Phase 2
This Phase IIa, randomized, double-blind, placebo-controlled, parallel group study will
evaluate the safety, efficacy and pharmacodynamics of basmisanil in adult participants with
severe motor impairment following an ischemic stroke.
A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics
Completed
Hoffmann-La Roche
Phase 2
This multicenter study assessed the effects of 24 weeks of basmisanil treatment on cognition
and functioning of stable schizophrenia participants treated with antipsychotics.
A Study to Evaluate the Safety and Efficacy of Basmisanil Treatment in Children With Dup15q Syndrome
Not yet recruiting
Hoffmann-La Roche
Phase 2
This study will evaluate the safety, efficacy, and pharmacodynamics of 52 weeks of basmisanil
treatment in children with Dup15q syndrome aged 2 to 11 years. The study will test the
hypothesis that modulation of a GABAA receptor subtype can address excessive receptor
function and positively impact core neurodevelopmental disease features in children with
Dup15q syndrome.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
